

Product	Dosage form	Indication	Dossier availability
<b>CENTRAL NERVOUS SYSTEM</b>			
Amitriptyline	Tablets 10, 25, 50 , 75 and 100 mg XR tablets 75 mg	Major depressive disorders and anxiety	Q2 2019 Q4 2019
Aripiprazole	Tablets 5, 10, 15, 20 and 30 mg	Schizophrenia, bipolar disorder	√
Clomethiazole [S]	Soft capsules 192 mg	Insomnia, restlessness, agitation	√
Clonazepam	Oral drops, solution 2.5 mg/ml Tablets 0.5 and 2 mg	Epilepsy	√ Q1 2020
Duloxetine	Gastro resistant hard capsules 30 and 60 mg	Major depression, neuropathic pain, anxiety	√
Eslicarbazepine	Film-coated tablets 800 mg	Epilepsy	Q3 2019
Ethosuximide	Oral solution 50 mg/ml Soft capsules 250 mg	Epilepsy, absence seizures	√
Fampridine	XR tablets 10 mg	Multiple sclerosis	Q1 2020
Fingolimod	Capsules 0.5 mg	Multiple sclerosis	Q3 2019
Levetiracetam	Film-coated tablets 250, 500, 750 and 1000 mg Granules for oral solution 250, 500, 750, 1000, and 1500 mg Oral solution 100 mg/ml	Epilepsy	√
Levomethadone	Oral solution 5 mg/ml Oral drops, solution 5 mg/ml	Pain, opioid maintenance therapy	√
Memantine hydrochloride	Film-coated tablets 5, 10, 15 and 20 mg Oral solution 10mg/ml	Alzheimer's disease	√
Methocarbamol	Film-coated tablets 750 mg Film-coated tablets 1.5 mg	Muscle spasms, pain	√ Q4 2019
Olanzapine	Film-coated tablets 2.5, 5, 7.5, 10, 15 and 20 mg Orodispersible tablets 5, 10, 15 and 20 mg	Psychosis, schizophrenia	√
Pipamperone	Tablets 40 and 120 mg	Psychosis, schizophrenia	√
Pramipexol	Tablets 0.088, 0.18, 0.35, 0.7 and 1.1 mg	Parkinson	√
Pregabalin	<b>Tablets</b> 25, 50, 75, 100, 150, 200, 225 & 300 mg	Neuropathic pain	√
Pyridostigmine	Film-coated tablets 60 mg	Myasthenia gravis	Q1 2020
Quetiapine	Film-coated tablets 25, 50, 100, 150, 200, 300 and 400 mg Orodispersible tablets 25 and 50 mg	Psychosis, schizophrenia, bipolar disorder	√ Q3 2020
Rasagiline	Tablets 1 mg	Parkinson	√
Risperidone	Film-coated tablets 0.5, 1, 2, 3, 4 and 6 mg	Psychosis, schizophrenia, bipolar disorder	√
Rotigotine	Patches 1, 2, 3, 4, 6 and 8 mg/24h	Parkinson	Q4 2019
Sodium Oxybate	Oral Solution 500 mg/ml	Narcolepsy	Q3 2019
Sulpiride	Tablets 50, 100 and 200 mg	Psychosis, schizophrenia	√
Sultiame [S]	Film-coated tablets 50, 100 and 200 mg	Epilepsy, convulsions	√
Tolcapone	Film-coated tablets 100 mg	Parkinson	√
Valproate	Oral solution 60 mg/mL and 300 mg/ml	Epilepsy	√
Zonisamide	Hard capsules 25, 50, 100 mg	Epilepsy	√

**[S] Singular Generics**

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

Product	Dosage form	Indication	Dossier availability
<b>OTHER THERAPEUTIC AREAS</b>			
<b>ANTIEMETICS</b>			
Ondansetron	Film-coated tablets 4 and 8 mg Orodispersible tablets 4 and 8 mg	Nausea & Vomiting	√
<b>ANTI-INFECTIVES</b>			
Azithromycin	Film-coated tablets 500 mg and Powder for oral suspension 200 mg/5 ml	Macrolide antibacterial	√
Ciprofloxacin otic	Ear drops, solution 1 mg <b>(unit dose)</b>	Otitis	√
Fluconazol	Capsules, hard 50, 100, 150 and 200 mg Powder for oral suspension 200 mg/5ml & 50mg/ 5ml	Antifungal	√
<b>CARDIOVASCULAR</b>			
Clopidogrel	Film-coated tablets 75 mg	Atherothrombosis	√
Enalapril	Tablets 5 and 20 mg	Hypertension	√
Enalapril + HCTZ	Tablets 20/12.5 mg	Hypertension	√
Imidapril [S]	Tablets 5, 10 and 20 mg	Hypertension	√
Irbesartan	Film-coated tablets 75, 150 and 300 mg	Hypertension	√
Irbesartan + HCTZ	Film-coated tablets 150/12.5, 300/12.5 & 300/25 mg	Hypertension	√
Lisinopril	Tablets 5 and 20 mg	Hypertension	√
Lisinopril + HCTZ	Tablets 20/12.5 mg	Hypertension	√
Prasugrel (Base)	Film-coated tablets 5 and 10 mg	Prophylaxis and therapy of thrombosis	√
Rivaroxaban	Film-coated tablets 10, 15 and 20 mg	Thrombosis, stroke	√
Valsartan	Film-coated tablets 40, 80, 160 and 320 mg	Hypertension	√
Valsartan + HCTZ	Film-coated tablets 80/12.5, 160/12.5, 320/12.5, 160/25, and 320/25 mg	Hypertension	√
<b>OPHTHALMIC PRODUCTS</b>			
Artificial tears Carmellose	2 mg eye drops, solution (unit dose)	Dry Eye	√
Artificial tears Hypromellose	0.5 ml eye drops, solution (unit dose)		
Bimatoprost	0.3 mg/ml eye drops, solution (0.4 ml unit dose)	Intraocular pressure	√
<b>PAIN</b>			
Dexketoprofen	Film-coated tablets 12.5 and 25 mg	Analgesic	√
Ketorolac	Film-coated tablets 10 mg	Analgesic	√
Paracetamol / Tramadol	Effervescent tablets 325/37.5 mg	Analgesic	√
Rizatriptan	<b>Orodispersible</b> tablets 5 and 10 mg	Migraine	√
Zolmitriptan	<b>Orodispersible</b> tablets 2.5 and 5 mg	Migraine	√
<b>RESPIRATORY</b>			
Desloratadine	Film-coated tablets 5 mg	Allergy	√
Loratadine	Film-coated tablets 10 mg	Allergy	√
Montelukast	Chewable tablets 4 & 5 mg and film-coated tablets 10 mg	Asthma, allergy	√

**[S] Singular Generics**

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

Product	Dosage form	Indication	Dossier availability
<b>OTHERS</b>			
Calcium Dobesilate [S]	Hard capsules 500 mg	Non proliferative diabetic retinopathy	√
Otilonium Bromide	Film-coated tablets 40 mg	Irritable bowel syndrome	√
Solifenacin	Film-coated tablets 5 and 10 mg	Overactive bladder, urinary incontinence	√

Product	Active Ingredients	Dosage form	Description	Launch date
<b>CNS NUTRACEUTICALS</b>				
Vivimind®	Homotaurine	Box of 40 tablets	Intended to protect memory and cognitive functions in MCI patients	Nov 2010
Viviflux®	Homotaurine + DHA + Folic Acid	Box of 20 capsules	Indicated for stroke primary and secondary prevention and for cerebrovascular disorders	Sep 2011
Vivifast®	Citicoline Cognizin® + Homotaurine + Vitamin E	Box of 20 tablets	Useful in the management of several types of cognitive disorders	Nov 2015
Seripnol®	L-Theanine + Magnolia + Ziziphus + Melatonin	Box of 28 sachets	Useful to promote relaxation and sleep	Mar 2012
Seripnol® drops	L-Theanine + Melatonin + Magnolia + Ziziphus	Oral drops. Bottle of 30 ml	Useful to promote relaxation and sleep	Apr 2014
Quetidia®	L-Theanine + Passiflora + Skullcap + Magnesium	Box of 30 tablets	Useful for the management of anxiety disorders	Sep 2014
Quetidia® oral solution	L-Theanine + Passiflora + Skullcap + Magnesium	Oral solution. Bottle of 150 ml	Useful for the management of anxiety disorders	Sep 2017
Triadenor®	N-Acetyl-Cystein + S-Adenosyl-LMethionine + Folic Acid	Box of 16 tablets	Useful for the management of depressive disorders	Nov 2014
Partena®	Magnesium + Parthenium + Andrographis Paniculata + Coenzyme Q10 + Vitamin B2	Box of 28 tablets	Rational combination for the prophylaxis of migraine, the nociceptive modulation and the reduction of tension states	Jan 2014
Noxiall®	PEA + Commiphora Myrrha + Rosmarinus Officinalis + Piper Nigrum (of which Beta Caryophyllene)	Box of 20 tablets	Useful to contrast chronic and neuropathic pain	Jan 2017
<b>UMP+Folic Acid+B12</b>	Uridine Monophosphate + Folic Acid + Vitamin B12	Box of 20 and 40 film-coated tablets	Useful for the treatment of spinal syndromes, neuralgias and polyneuropathies	<b>Jul 2018</b>

**[S] Singular Generics**

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.